|
AIDS Research and Human Retroviruses
Enfuvirtide Is Active against HIV Type 1 Group O
To cite this article:
Eva Poveda, Pablo Barreiro, Berta Rodés, Vincent Soriano.
AIDS Research and Human Retroviruses.
June 2005,
21(6): 583-585.
doi:10.1089/aid.2005.21.583.
Eva Poveda Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. Pablo Barreiro Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. Berta Rodés Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. Vincent Soriano Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. A high diversity within the HR1/HR2 regions of viral gp41 and one natural change (N42D) within the 36–45 aa domain in HIV-1 group O in comparison with HIV-1 group M isolates have led us to suspect that enfuvirtide (ENF) should not be active against HIV-1 group O. We analyzed in vitro and in vivo the antiviral activity of ENF against HIV-1 group O isolates. The IC50 at baseline was 0.15 ± 0.028 µg/ml in a clinically derived virus specimen. After initiating treatment with ENF, a significant decline in plasma HIV-RNA and CD4 gain was noticed in one patient. Therefore, individuals with HIV-1 group O strains might benefit from ENF therapy.  This paper was cited by:Raltegravir and Etravirine Are Active against HIV Type 1 Group O Verónica Briz, Carolina Garrido, Eva Poveda, Judit Morello, Pablo Barreiro, Carmen de Mendoza, Vincent Soriano AIDS Research and Human Retroviruses. Feb 2009, Vol. 25, No. 2: 225-227 Abstract | Full Text PDF | Reprints & PermissionsReassessment of enfuvirtide's role in the management of HIV-1 infection Patricia Marr, Sharon Walmsley Expert Opinion on Pharmacotherapy. Oct 2008, Vol. 9, No. 13: 2349-2362 CrossRef gp41 Sequence Variability in HIV Type 1 Non-B Subtypes Infected Patients Undergoing Enfuvirtide Pressure Roberta D'Arrigo, Massimo Ciccozzi, Caterina Gori, Stefania Montieri, Stefano Aquaro, Rita Bellagamba, Evangelo Boumis, Giovanni Di Perri, Daniele Pizzi, Andrea Antinori, Giovanni Rezza, Carlo Federico Perno AIDS Research and Human Retroviruses. Oct 2007, Vol. 23, No. 10: 1296-1302 Abstract | Full Text PDF | Reprints & PermissionsClinical impact of HIV-1 subtype: are there important differences? Susan M Graham Future HIV Therapy. Oct 2007, Vol. 1, No. 3: 273-290 CrossRef Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants Africa Holguín, Eva Ramírez De Arellano, Vincent Soriano AIDS Research and Human Retroviruses. Sep 2007, Vol. 23, No. 9: 1067-1074 Abstract | Full Text PDF | Reprints & PermissionsTipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients Carmen de Mendoza, Judit Morelló, Pilar Garcia-Gascó, Sonia Rodríguez-Novoa, Vincent Soriano Expert Opinion on Pharmacotherapy. May 2007, Vol. 8, No. 6: 839-850 CrossRef Diversity of HIV in Rural Burkina Faso Denis M Tebit, Jean Ganame, Kanokporn Sathiandee, Youssouf Nagabila, Boubacar Coulibaly, Hans-Georg Krausslich JAIDS Journal of Acquired Immune Deficiency Syndromes. Nov 2006, Vol. 43, No. 2: 144-152 CrossRef Inhibition of HIV-1 group M and O isolates by fusion inhibitors Raghavan Chinnadurai, Jan M??nch, Matthias T Dittmar, Frank Kirchhoff AIDS. Dec 2005, Vol. 19, No. 16: 1919???1922 CrossRef |
|
TOC Alert
CiteULike
Delicious
Digg This
Facebook
Newsvine